Aceto Corporation execute its first generic biopharmaceutical agreement
Aceto Corporation announced that it signed an agreement with Three Rivers Pharmaceuticals, LLC to bring three generic biopharmaceutical products to market.
Under the agreement, Aceto will source the active pharmaceutical ingredients, manage the regulatory and quality control functions of production, and supply the final dosage form of the products to Three Rivers. Three Rivers will file applications with the appropriate regulatory agencies and market the products in the U.S., Europe and Japan. Aceto anticipates Three Rivers will submit regulatory applications within the next year, with commercialization of the products expected in 2007.
The agreement provides for revenue sharing between the two companies based on Three Rivers' final selling prices, and will continue for a minimum term of ten years from the date of initial commercial sales.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Bristol-Myers Squibb and QIAGEN collaborate - Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies
More efficient biosolar cells modelled on nature - By combining light-collecting and photosynthesis proteins of different types, more energy can be produced
AI performs as well as medical specialists in analyzing lung disease
Merck Advances to Eighth Place in the 2012 Access to Medicine Index
Evonik achieves major biotech breakthrough with a new animal-free and fermentation-based collagen platform - Recombinant collagen mimics attributes of human collagen
Bacteria Free Themselves with Molecular “Speargun”
Paper-based device developed for rapid diagnosis of lung diseases - CSIC researchers have coordinated the design of an instrument that combines paper microfluidics and electrochemical transduction.
SciGene Moves to Larger Manufacturing and Research Space
Complex production and sales processes weaken a company's competitiveness - Engineering, chemicals and pharmaceuticals need to catch up
Innogenetics extends its diagnostics product portfolio for Alzheimer's disease with new products
